NEWS HIGHLIGHTSMedia Articles Related to Multaq (Dronedarone)
Seasoning May Cut Salt Needs in Hypertension (CME/CE)
Source: MedPage Today Primary Care [2013.05.18]
SAN FRANCISCO (MedPage Today) -- A greater taste for salt among older hypertensive adults might be sated by seasoning instead, a small experimental study showed.
Surprising Findings On Hypertension In Adolescents
Source: Hypertension News From Medical News Today [2013.05.07]
Teenagers with high blood pressure appear to have better psychological adjustment and enjoy higher quality of life than those with normal blood pressure, suggests a study in the May issue of Psychosomatic Medicine: Journal of Biobehavioral Medicine, the official journal of the American Psychosomatic Society...
Safety-Net Clinics Face Challenges Controlling Hypertension In Their Patients
Source: Hypertension News From Medical News Today [2013.04.19]
Federally funded safety-net clinics for the uninsured lag behind other health care providers in controlling blood pressure among the low-income patients who rely on them for care, a new Michigan State University analysis suggests...
Relationship Between Obesity, Heart Disease And Hypertension
Source: Hypertension News From Medical News Today [2013.04.13]
Obesity, heart disease, and high blood pressure (hypertension) are all related, but understanding the molecular pathways that underlie cause and effect is complicated...
Preeclampsia (Pregnancy Induced Hypertension)
Source: MedicineNet Hydronephrosis Specialty [2012.05.21]
Title: Preeclampsia (Pregnancy Induced Hypertension)
Category: Diseases and Conditions
Created: 11/14/1998 4:06:00 PM
Last Editorial Review: 5/21/2012 12:00:00 AM
Published Studies Related to Multaq (Dronedarone)
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). [2011.04.01]
Dronedarone is a multi-channel-blocking drug for the treatment of patients with atrial fibrillation (AF) or atrial flutter (AFL) with rate- and rhythm-controlling properties...
Impact of dronedarone on hospitalization burden in patients with atrial
fibrillation: results from the ATHENA study. [2011]
CONCLUSION: Dronedarone reduced the risk for CV hospitalization and the total
Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure. [2010.12]
PURPOSE: Dronedarone is a novel multichannel blocker with antiadrenergic and vasodilatory properties. The aim of this study was to investigate the effects of dronedarone on functional capacity in patients with severe left ventricular (LV) dysfunction and compensated stable heart failure (HF)... CONCLUSIONS: Short-term treatment with dronedarone did not affect exercise capacity and did not decrease LVEF in patients with severe LV dysfunction and compensated HF.
Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. [2010.12]
Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. The drug was developed for the treatment of atrial fibrillation (AF)...
Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials. [2010.05.14]
Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation. The drug was developed for the treatment of atrial fibrillation (AF)...
Clinical Trials Related to Multaq (Dronedarone)
A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY) [Recruiting]
The purpose of this study is to evaluate whether treatment with ranolazine or low dose
dronedarone reduces atrial fibrillation burden (AFB) in subjects with paroxysmal atrial
fibrillation (PAF), and whether combination therapy (ranolazine and low dose dronedarone) is
superior to individual drug therapy in reducing AFB.
Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation [Not yet recruiting]
The purpose of this study is to accurately investigate the efficacy of dronedarone in
maintaining sinus rhythm and decreasing AFB in patients with paroxysmal atrial fibrillation
as compared with placebo. This has never previously been performed using pacemaker Holter
monitoring which provides detailed information of atrial arrhythmia patterns the entire
study period. Additionally detailed patient symptom self assessment and questionnaires will
be collected. The study design will be double blinded crossover with each phase lasting 3
months.
Effects of Dronedarone on Cardiac Geometry and Function in Patients With Atrial Fibrillation and Left Atrial Enlargement [Not yet recruiting]
Primary Objective:
- Evaluate the effect of dronedarone versus placebo (standard therapy) in slowing the
progression of adverse left atrial remodeling in patients with atrial fibrillation (AF)
following 12 months of treatment
Secondary Objectives:
- Evaluate the effects of dronedarone versus placebo on left atrial function
- Evaluate the effects of dronedarone versus placebo on left atrial dimension
- Evaluate the effects of dronedarone versus placebo on left ventricular function (LVEF,
E, E', A, E/E')
- Evaluate the safety and tolerability of dronedarone
Dose Ranging Study of Dronedarone for the Control of Ventricular Rate in Japanese Patients With Permanent Atrial Fibrillation [Recruiting]
Primary Objective:
- To assess the efficacy of dronedarone versus placebo for the control of ventricular rate
in patients with permanent atrial fibrillation (AF).
Secondary Objective:
- To assess the safety and tolerability of dronedarone after repeated oral doses of 300
mg, 400 mg, or 600 mg twice daily in the selected population.
- To document SR33589 and SR35021 trough plasma levels at steady state.
Dronaderone to Prevent Recurrent Implantable Cardioverter Defibrillator (ICD) Shocks [Not yet recruiting]
Recurrent ICD shocks are a serious problem in pts with ICD. Treatment failure with other
antiarrhythmics and ablation are common. Dronedarone is a new antiarrhythmic drug with ion
channel properties similar to amiodarone.
Several case reports have shown promising results with Dronedarone for this patient
population.
Reports of Suspected Multaq (Dronedarone) Side Effects
Atrial Fibrillation (159),
Dyspnoea (74),
Blood Creatinine Increased (66),
Fatigue (43),
Dizziness (37),
Diarrhoea (37),
Nausea (27),
Asthenia (27),
Hyperthyroidism (25),
Interstitial Lung Disease (23), more >>
|
